{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:02:13Z","timestamp":1774425733094,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejmech.2021.113734","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T06:01:30Z","timestamp":1628402490000},"page":"113734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoBS522L strain and display a different binding mode at the RNAP \u03b2-subunit site compared to rifampicin"],"prefix":"10.1016","volume":"225","author":[{"given":"Mire","family":"Zloh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7507-0423","authenticated-orcid":false,"given":"Tanya","family":"Parish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2910","authenticated-orcid":false,"given":"Federico","family":"Brucoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113734_bib1","first-page":"146","article-title":"Rifomycin, a new antibiotic; preliminary report","volume":"14","author":"Sensi","year":"1959","journal-title":"Farmaco. [Sci. ]"},{"key":"10.1016\/j.ejmech.2021.113734_bib2","volume":"vol. 21","author":"McHugh","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113734_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev.mi.26.100172.000505","article-title":"A\u00a0semisynthetic derivative of rifamycin-A prototype for the future","volume":"26","author":"Lester","year":"1972","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2021.113734_bib4","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of the development of rifampin","volume":"5","author":"Sensi","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113734_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000220462","article-title":"Rifampicin: a new orally active rifamycin","volume":"11","author":"Maggi","year":"1966","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejmech.2021.113734_bib6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.7164\/antibiotics.34.1026","article-title":"Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative","volume":"34","author":"Arioli","year":"1981","journal-title":"J.\u00a0Antibiot."},{"key":"10.1016\/j.ejmech.2021.113734_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/clinids\/9.3.519","article-title":"Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases","volume":"9","author":"O'Brien","year":"1987","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113734_bib8","series-title":"World Health Organization Model List of Essential Medicines: 21st List 2019","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113734_bib9","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2174\/1381612043383287","article-title":"In\u00a0vitro and in\u00a0vivo activities of new rifamycin derivatives against mycobacterial infections","volume":"10","author":"Lounis","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113734_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins\u2013obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2021.113734_bib11","first-page":"8","article-title":"Pharmokinetics of new long-acting rifamycin-derivatives in man","volume":"61","author":"Vischer","year":"1986","journal-title":"Bull. Int. Union Tuberc."},{"key":"10.1016\/j.ejmech.2021.113734_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber. Lung Dis."},{"key":"10.1016\/j.ejmech.2021.113734_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tube.2017.04.008","article-title":"Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: rifampicin and pyrazinamide in the post whole genome sequencing era","volume":"105","author":"Unissa","year":"2017","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2021.113734_bib14","series-title":"Global Tuberculosis Report 2019","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113734_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113734_bib16","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1073\/pnas.0802822105","article-title":"Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center","volume":"105","author":"Feklistov","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2021.113734_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diagmicrobio.2016.01.019","article-title":"Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex","volume":"85","author":"Berrada","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113734_bib18","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JCM.00691-14","article-title":"Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis","volume":"52","author":"Jamieson","year":"2014","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.ejmech.2021.113734_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejmech.2016.03.061","article-title":"Structure\u2013activity relationship studies of new rifamycins containing l-amino acid esters as inhibitors of bacterial RNA polymerases","volume":"116","author":"Czerwonka","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113734_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2019.02.009","article-title":"Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin","volume":"167","author":"Pyta","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113734_bib21","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1039\/c2ob00008c","article-title":"Intramolecular proton transfer impact on antibacterial properties of ansamycin antibiotic rifampicin and its new amino analogues","volume":"10","author":"Pyta","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2021.113734_bib22","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.1039\/c2ob26317c","article-title":"A\u00a0new model of binding of rifampicin and its amino analogues as zwitterions to bacterial RNA polymerase","volume":"10","author":"Pyta","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2021.113734_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejmech.2014.07.066","article-title":"Structure and evaluation of antibacterial and antitubercular properties of new basic and heterocyclic 3-formylrifamycin SV derivatives obtained via \u2018click chemistry\u2019approach","volume":"84","author":"Pyta","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113734_bib24","first-page":"358","article-title":"The reaction of 3-formylrifamycin SV with sulphonium and phosphonium ylides","volume":"29","author":"Cricchio","year":"1974","journal-title":"Farmaco. [Sci. ]"},{"key":"10.1016\/j.ejmech.2021.113734_bib25","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1248\/cpb.32.4388","article-title":"Reaction of 3-formylrifamycin S with secondary amines","volume":"32","author":"Taguchi","year":"1984","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2021.113734_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tet.2014.10.079","article-title":"Rifamycin antibiotics\u2014new compounds and synthetic methods. Part 4: study of the reaction of 3-formylrifamycin SV with secondary amines and ketones","volume":"71","author":"Bujnowski","year":"2015","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2021.113734_bib27","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/jm201716n","article-title":"Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases","volume":"55","author":"Gill","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113734_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0041-3879(87)90053-5","article-title":"In\u00a0vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria","volume":"68","author":"Dickinson","year":"1987","journal-title":"Tubercle"},{"key":"10.1016\/j.ejmech.2021.113734_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/cr030112j","article-title":"Rifamycin mode of action, resistance, and biosynthesis","volume":"105","author":"Floss","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2021.113734_bib30","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1021\/acsinfecdis.9b00176","article-title":"Specific interactions between rifamycin antibiotics and water influencing ability to overcome natural cell barriers and the range of antibacterial potency","volume":"5","author":"Pyta","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113734_bib31","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cphc.201402892","article-title":"Regioselective long-range proton transfer in new rifamycin antibiotics: a process in which crown ethers act as stronger Br\u00f8nsted bases than amines","volume":"16","author":"Pyta","year":"2015","journal-title":"ChemPhysChem"},{"key":"10.1016\/j.ejmech.2021.113734_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075245","article-title":"Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis","volume":"8","author":"Ioerger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113734_bib33","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1073\/pnas.091096998","article-title":"Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-\u03b1\/\u03b2","volume":"98","author":"Manca","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2021.113734_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molcel.2017.03.001","article-title":"Structural basis of Mycobacterium tuberculosis transcription and transcription inhibition","volume":"66","author":"Lin","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2021.113734_bib35","first-page":"64","article-title":"Probing the molecular mechanism of rifampin resistance caused by the point mutations S456L and D441V on Mycobacterium tuberculosis RNA polymerase through Gaussian accelerated molecular dynamics simulation","author":"Zhang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113734_bib36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cell.2005.07.014","article-title":"Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins","volume":"122","author":"Artsimovitch","year":"2005","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.ejmech.2021.113734_bib37","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1128\/JB.00166-10","article-title":"Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories","volume":"192","author":"Ioerger","year":"2010","journal-title":"J.\u00a0Bacteriol."},{"key":"10.1016\/j.ejmech.2021.113734_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060531","article-title":"A\u00a0Dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis","volume":"8","author":"Ollinger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113734_bib39","series-title":"SC'06: Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing","first-page":"43","article-title":"In scalable algorithms for molecular dynamics simulations on commodity clusters","author":"Bowers","year":"2006"},{"key":"10.1016\/j.ejmech.2021.113734_bib40","series-title":"Schr\u00f6dinger Release 2020-1: Desmond Molecular Dynamics System","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113734_bib41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2021.113734_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/B:JCAM.0000035186.90683.f2","article-title":"VEGA\u2013an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming","volume":"18","author":"Pedretti","year":"2004","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2021.113734_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1093-3263(02)00123-7","article-title":"VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs","volume":"21","author":"Pedretti","year":"2002","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2021.113734_bib44","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.bmcl.2016.06.013","article-title":"Enriching screening libraries with bioactive fragment space","volume":"26","author":"Zhang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113734_bib45","first-page":"1","article-title":"Avogadro: an advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J.\u00a0Cheminf."},{"key":"10.1016\/j.ejmech.2021.113734_bib46","series-title":"Discovery Studio Modeling Environment","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113734_bib47","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev. A"},{"key":"10.1016\/j.ejmech.2021.113734_bib48","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1021\/j100078a035","article-title":"A\u00a0multiple-time-step molecular dynamics algorithm for macromolecules","volume":"98","author":"Humphreys","year":"1994","journal-title":"J.\u00a0Phys. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113734_bib49","doi-asserted-by":"crossref","first-page":"o209","DOI":"10.1107\/S0108270112015296","article-title":"Redetermination of rifampicin pentahydrate revealing a zwitterionic form of the antibiotic","volume":"68","author":"Wicher","year":"2012","journal-title":"Acta Crystallogr. C"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113734_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00894-012-1667-x","article-title":"Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters","volume":"19","author":"Stewart","year":"2013","journal-title":"J.\u00a0Mol. Model."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:31:57Z","timestamp":1759329117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421005833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":50,"alternative-id":["S0223523421005833"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113734","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoBS522L strain and display a different binding mode at the RNAP \u03b2-subunit site compared to rifampicin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113734"}}